Cytosorbents (CTSO) Return on Capital Employed (2011 - 2026)
Cytosorbents' (CTSO) quarterly Return on Capital Employed came in at 53.34% in Q1 2026, down 1348.0% YoY from 4.27% in Q1 2025, and down 27.51% on a QoQ basis from 41.84% in Q4 2025.
Cytosorbents (CTSO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cytosorbents (CTSO) has 15 years of Return on Capital Employed data on file, last reported at 53.34% in Q1 2026.
- Quarterly Return on Capital Employed fell 1348.0% year-over-year to 53.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53.34% (down 1348.0% YoY) and the FY2025 annual result came in at 40.89%, down 11.0% from the prior year.
- Return on Capital Employed fell to 53.34% in Q1 2026, from 41.84% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 37.43% in Q3 2025 to a low of 86.14% in Q4 2023.
- A 5-year average of 55.27% and a median of 53.34% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 4285 bps — and 2024, when it surged 4258 bps.
- Tracing CTSO's Return on Capital Employed over 5 years: stood at 59.43% in 2022, then tumbled by 45 bps to 86.14% in 2023, then soared by 49 bps to 43.56% in 2024, then increased by 4 bps to 41.84% in 2025, then retreated by 28 bps to 53.34% in 2026.
- The last three Return on Capital Employed figures came in at 53.34% (Q1 2026), 41.84% (Q4 2025), and 37.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.79 Bn | 195.19 Bn | 7.27 Bn | 7.98% |
| 2 | Stryker | 125.96 Bn | 122.49 Bn | 4.50 Bn | 13.69% |
| 3 | Medtronic | 118.43 Bn | 109.21 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 73.13 Bn | 72.59 Bn | 3.85 Bn | 10.83% |
| 5 | Edwards Lifesciences | 51.63 Bn | 47.38 Bn | 1.35 Bn | 11.99% |
| 6 | Dexcom | 34.60 Bn | 32.65 Bn | 830.00 Mn | 27.21% |
| 7 | GE HealthCare Technologies | 33.71 Bn | 31.60 Bn | 2.18 Bn | 9.47% |
| 8 | Koninklijke Philips | 26.17 Bn | 22.85 Bn | 4.55 Bn | 12.84% |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 12.08% |
| 10 | Cytosorbents | 19.53 Mn | 15.12 Mn | 7.05 Mn | -84.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.85% |
| Mar 31, 2026 | -53.34% |
| Dec 31, 2025 | -41.84% |
| Sep 30, 2025 | -37.43% |
| Jun 30, 2025 | -39.77% |
| Mar 31, 2025 | -39.86% |
| Dec 31, 2024 | -43.56% |
| Sep 30, 2024 | -53.07% |
| Jun 30, 2024 | -61.53% |
| Mar 31, 2024 | -75.02% |
| Dec 31, 2023 | -86.14% |
| Sep 30, 2023 | -73.45% |
| Jun 30, 2023 | -66.32% |
| Mar 31, 2023 | -62.13% |
| Dec 31, 2022 | -59.43% |
| Sep 30, 2022 | -61.34% |
| Jun 30, 2022 | -46.66% |
| Mar 31, 2022 | -38.60% |
| Dec 31, 2021 | -28.94% |
| Sep 30, 2021 | -18.49% |